BOZEMAN, Mont. -- Montana State University researchers and their collaborators have published their findings about a chemical compound that shows potential for treating rheumatoid arthritis.
The paper ran in the June issue of the Journal of Pharmacology and Experimental Therapeutics (JPET), and one of its illustrations is featured on the cover. JPET is a leading scientific journal that covers all aspects of pharmacology, a field that investigates the effects of drugs on biological systems and vice versa.
"This journal is one of the top journals that reports new types of therapeutics that are being developed," said Mark Quinn, senior author on the paper and a professor in MSU's Department of Microbiology and Immunology. The department is part of the College of Agriculture and the College of Letters and Science.
Rheumatoid arthritis is a chronic autoimmune disorder that affects an estimated 1.3 million people in the world, Quinn said. Characterized by stiff, swollen joints, it's a progressive disease that occurs when the body's immune system attacks its own cells. Inflammation in the lining of the joints leads to loss of bone and cartilage. People who have rheumatoid arthritis lose mobility and joint function without adequate treatment.
New kinds of drugs have been developed for treating the disease, Quinn said. Called biological drugs, or "biologics," they are made from genetically engineered proteins or antibodies that act on substances in the immune system. When used to treat rheumatoid arthritis, they interrupt signals that fuel the inflammatory process. Two such drugs are ENBREL and HUMIRA.
Biologics can be expensive, however, and some people don't respond to them, Quinn said. Some people respond at first, but not forever.
"There is a real need to develop new kinds of drugs that are different," Quinn said. "They could be combined with other available drugs or replace drugs that aren't working for patients."
Researchers in his laboratory and elsewhere identified a new chemical compound, called IQ-1S, in a previous study, Quinn said. Then they conducted a new study to understand how the small-molecule compound works against rheumatoid arthritis. They explained their findings in the JPET paper.
The paper said IQ-1S significantly reduced the severity of collagen-induced arthritis, which is a model for rheumatoid arthritis, and inhibited the destruction of cartilage and bone. The compound worked because it targeted kinase proteins that send out signals for destructive and inflammatory activities. Since IQ-1S inhibited the kinase activities, it suppressed inflammation in joint tissue and lymph node cells.
###
Eight scientists collaborated on the study that was published in JPET. In addition to Quinn, the MSU researchers were senior scientist Igor Schepetkin and research associates Liliya Kirpotina and Irina Kochetkova.
Their collaborators at other institutions were Deepa Hammaker and Gary Firestein from the University of California, San Diego; Andrei Khlebnikov from Altai State Technical University and Tomsk Polytechnic University in Russia; and Sergey Lyakhov from the National Academy of Sciences in the Ukraine.
Research reported in this press release was supported by the National Institutes of Health National Institute of General Medical Sciences IDeA Program under award number P30GM110732 and the National Institute of Arthritis and Musculoskeletal and Skin Diseases under award number R01AR47825, a United States Department of Agriculture National Institute of Food and Agriculture Hatch project, and the Montana State University Agricultural Experiment Station.
The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health, USDA, or Montana Agricultural Experiment Station.
Journal
Journal of Pharmacology and Experimental Therapeutics